Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
Legend Biotech (NASDAQ: LEGN), a global leader in cell therapy, announced the appointment of Peter Salovey, Ph.D., President Emeritus of Yale University, to its Board of Directors, effective August 9, 2024. Dr. Salovey brings extensive experience in medical research and public health, having led significant developments at Yale, including expanding faculty and launching new schools. His expertise in health communication and human emotion research, including founding the Yale Center for Emotional Intelligence, is expected to bring valuable insights to Legend Biotech.
Legend Biotech (NASDAQ: LEGN), leader globale nella terapia cellulare, ha annunciato la nomina di Peter Salovey, Ph.D., Presidente Emerito della Yale University, nel suo Consiglio di Amministrazione, a partire dal 9 agosto 2024. Il Dr. Salovey porta con sé una vasta esperienza nella ricerca medica e nella salute pubblica, avendo guidato importanti sviluppi presso Yale, tra cui l'espansione del corpo docente e il lancio di nuove scuole. La sua esperienza nella comunicazione della salute e nella ricerca sulle emozioni umane, incluso il fondare il Centro per l'Intelligenza Emotiva di Yale, si prevede porterà preziose intuizioni a Legend Biotech.
Legend Biotech (NASDAQ: LEGN), líder global en terapia celular, anunció el nombramiento de Peter Salovey, Ph.D., Presidente Emérito de la Universidad de Yale, en su Junta Directiva, a partir del 9 de agosto de 2024. El Dr. Salovey aporta una amplia experiencia en investigación médica y salud pública, habiendo liderado importantes desarrollos en Yale, incluyendo la expansión de la facultad y el lanzamiento de nuevas escuelas. Se espera que su experiencia en comunicación de la salud y en investigación sobre emociones humanas, incluida la fundación del Centro de Inteligencia Emocional de Yale, aporte valiosos conocimientos a Legend Biotech.
전설 생명공학 (NASDAQ: LEGN), 세포 치료의 글로벌 리더, 와일의 피터 살로베이 박사(Ph.D.)를 이사회에 임명했다고 발표했습니다. 이는 2024년 8월 9일부터 시행됩니다. 살로베이 박사는 의료 연구 및 공공 건강 분야에서 광범위한 경험을 가지고 있으며, 예일대학교에서 교수진 확장 및 새로운 학교 설립 등의 중요 개발을 주도하였습니다. 건강 커뮤니케이션 및 인간 감정 연구에 대한 그의 전문성, 특히 예일 감정 지능 센터 설립에 대한 경험은 전설 생명공학에 귀중한 통찰력을 제공할 것으로 예상됩니다.
Legend Biotech (NASDAQ: LEGN), un leader mondial dans la thérapie cellulaire, a annoncé la nomination de Peter Salovey, Ph.D., Président Émérite de l'Université de Yale, à son Conseil d'Administration, à compter du 9 août 2024. Le Dr Salovey apporte une vaste expérience en recherche médicale et en santé publique, ayant dirigé d'importants développements à Yale, y compris l'expansion du corps professoral et le lancement de nouvelles écoles. Son expertise en communication de la santé et en recherche sur les émotions humaines, y compris la fondation du Yale Center for Emotional Intelligence, devrait apporter des perspectives précieuses à Legend Biotech.
Legend Biotech (NASDAQ: LEGN), ein weltweit führendes Unternehmen im Bereich Zelltherapie, gab die Ernennung von Peter Salovey, Ph.D., Präsident Emeritus der Yale University, in seinen Verwaltungsrat bekannt, die am 9. August 2024 in Kraft tritt. Dr. Salovey bringt umfassende Erfahrung in der medizinischen Forschung und der öffentlichen Gesundheit mit, da er bedeutende Entwicklungen an der Yale geleitet hat, darunter die Erweiterung der Fakultät und die Gründung neuer Schulen. Sein Fachwissen in Gesundheitskommunikation und der Forschung zu menschlichen Emotionen, einschließlich der Gründung des Yale Center for Emotional Intelligence, wird voraussichtlich wertvolle Einblicke für Legend Biotech bringen.
- Appointment of Peter Salovey, Ph.D., to the Board of Directors brings extensive medical research and public health experience.
- Dr. Salovey's background in health communication and human emotion research can provide strategic insights for Legend Biotech's growth.
- Dr. Salovey's leadership at Yale, including expanding faculty and launching new schools, demonstrates strong capability in guiding organizational development.
- None.
SOMERSET, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Peter Salovey, Ph.D., President Emeritus of Yale University, to its Board of Directors. Dr. Salovey will serve as an independent director, effective August 9.
“We are pleased to welcome Dr. Salovey to the Legend Board,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Dr. Salovey’s deep experience and wealth of knowledge in medical research and public health will be invaluable to Legend and offer a new and diverse perspective. We look forward to his insights and contributions to the strategic decisions that will strengthen and drive further growth for our Company.”
Dr. Salovey is the Chris Argyris Professor of Psychology and was the twenty-third president of Yale University, serving as president from July 2013 to June 2024. As President, Dr. Salovey led the development of new programs and facilities across the schools and departments of Yale, including restructuring and expanding the Faculty of Arts and Sciences and the School of Engineering and Applied Science, launching the Jackson School of Global Affairs, transitioning the Yale School of Public Health into a self-supporting independent school, and opening two new residential colleges to expand the undergraduate student population by
“There has been a lot of momentum within the CAR-T space over the past several years, as it has the potential to transform the treatment paradigm for multiple myeloma patients,” said Dr. Salovey. “I am honored by the opportunity to be part of the Legend Board and collaborate with such a high-caliber organization and leadership team working to bring innovative therapies to patients with debilitating and life-threatening diseases.”
Dr. Salovey received his an A.B. (psychology) and A.M. (sociology) from Stanford University and earned an M.S., M.Phil., and Ph.D. in psychology from Yale University. He completed his internship in clinical health psychology at the West Haven Veterans Administration Medical Center and is a licensed clinical psychologist in the State of Connecticut.
ABOUT LEGEND BIOTECH
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell (gd T) and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com
FAQ
When will Peter Salovey, Ph.D., join the Board of Directors of Legend Biotech?
What experience does Peter Salovey, Ph.D., bring to Legend Biotech?
How might Peter Salovey, Ph.D.'s appointment impact Legend Biotech (NASDAQ: LEGN)?
What are some of Peter Salovey, Ph.D.'s notable achievements?
